What are the next steps in managing a patient with osteoporosis who is taking alendronate (Fosamax) but remains osteoporotic?

Management of Persistent Osteoporosis Despite Alendronate Therapy

For patients remaining osteoporotic on alendronate (Fosamax), the next step depends critically on fracture risk stratification: switch to an anabolic agent (teriparatide, abaloparatide, or romosozumab) for very high-risk patients, or transition to denosumab or IV zoledronate for high-risk patients who have not achieved treatment goals.

Initial Assessment Required

Before changing therapy, you must:

• Verify medication adherence and proper administration 1. Alendronate must be taken with plain water first thing in the morning, 30 minutes before any food/beverage/medication, while remaining upright. Even coffee or orange juice markedly reduces absorption.

• Assess for secondary causes of osteoporosis: vitamin D deficiency, calcium malabsorption (celiac disease, gastric bypass, Crohn's disease), hyperparathyroidism, hyperthyroidism, hypogonadism, or medications (glucocorticoids) 2.

• Measure bone turnover markers (BTMs) if available to assess biological response.

• Review fracture history during treatment: new fractures on therapy indicate treatment failure requiring immediate escalation.

Risk Stratification Determines Next Steps

Very High Risk Patients (Switch to Anabolic Therapy First)

Indicators of very high risk include 2:

• Multiple vertebral fractures
• Recent hip fracture
• Very low T-scores (≤ -3.0)
• Fracture while on bisphosphonate therapy
• Advanced age with frailty
• High fall risk

Recommended sequence 2:

1. Romosozumab (first choice for very high risk):

   • 210 mg subcutaneous monthly for 12 months
   • Produces dramatic BMD increases (9.8% lumbar spine, 3.2% femoral neck at 12 months) 2
   • Reduces vertebral fractures by 73% vs placebo, 34% vs alendronate 2
   • Critical contraindication: Do NOT use if recent MI or stroke, or high cardiovascular risk (black box warning) 2
   • Must be followed by antiresorptive therapy (denosumab or bisphosphonate) 2

2. Teriparatide or Abaloparatide (alternative anabolic options):

   • Use for up to 24 months maximum 2
   • Important caveat: Response is "blunted" in patients previously on bisphosphonates—BMD and BTM changes are attenuated 2
   • Must be followed immediately by antiresorptive therapy (no washout period) to prevent rapid bone loss 2
   • Contraindications: Paget's disease, prior skeletal radiation, unexplained elevated alkaline phosphatase, open epiphyses 2

High Risk Patients (Switch to Alternative Antiresorptive)

For patients at high but not very high risk 2:

1. Denosumab (60 mg subcutaneous every 6 months):

   • Produces further BMD increases when switched from bisphosphonates 3
   • No renal dose adjustment needed 2
   • Critical warning: NEVER stop denosumab abruptly—causes severe rebound bone loss and multiple vertebral fractures 2, 4
   • Exit strategy mandatory: Must transition to bisphosphonate (typically zoledronate) when discontinuing 4

2. Zoledronate (5 mg IV annually):

   • Maintains therapeutic effects when switched from alendronate 3
   • Consider if adherence to oral therapy is problematic
   • Requires creatinine clearance >35 mL/min 2

3. Strontium ranelate (where available):

   • Produces further BMD increases after bisphosphonate 3

Common Pitfalls to Avoid

Do NOT switch to teriparatide/abaloparatide immediately after stopping denosumab—BMD decreases for 6-12 months 2. However, these anabolic agents may be added to ongoing denosumab therapy.

Do NOT use romosozumab as monotherapy—it requires subsequent antiresorptive treatment to maintain gains 2.

Do NOT forget calcium and vitamin D supplementation—ensure adequate intake (calcium 1200 mg/day, vitamin D to maintain 25-OH vitamin D >30 ng/mL) 2, 1.

Do NOT ignore renal function—bisphosphonates contraindicated with GFR <30-35 mL/min; denosumab is the safer choice in renal insufficiency 2.

Monitoring During Transition

• Repeat DXA scan 1-2 years after therapy change to assess response 2
• Monitor serum calcium when starting denosumab or anabolic agents (risk of hypocalcemia) 1
• Assess for new fractures clinically and radiographically if symptomatic

Duration and Sequencing

After anabolic therapy (12-24 months), immediately transition to antiresorptive 2:

• Alendronate 70 mg weekly, or
• Denosumab 60 mg every 6 months, or
• Zoledronate 5 mg annually

Continue antiresorptive therapy until patient no longer meets high-risk criteria, typically requiring years of treatment 2, 5.

The evidence strongly supports that sequential therapy strategies produce superior outcomes compared to continuing failed bisphosphonate monotherapy, particularly for very high-risk patients 2, 5.